Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 5, 2004 - Issue 8
Submit an article Journal homepage
150
Views
9
CrossRef citations to date
0
Altmetric
Drug Evaluation

Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease

Mark T Dransfield University of Alabama at Birmingham, Division of Pulmonary, Allergy and Critical Care Medicine, 215 THT, 1900 University Blvd, Birmingham, AL 35294, USA. [email protected]
&
William C Bailey University of Alabama at Birmingham, Division of Pulmonary, Allergy and Critical Care Medicine, 215 THT, 1900 University Blvd, Birmingham, AL 35294, USA
Pages 1815-1826 | Published online: 25 Feb 2005

Bibliography

  • PAUWELS RA, BUIST AS, CAL VERLEY PM, JENKINS CR, HURD SS: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Respir: Grit. Care Med. (2001) 163:1256–1276.
  • ••This article summarises the GOLDrecommendations for the diagnosis and management of COPD. The updated version is available at http://www.goldcopd.com
  • MURRAY CJ, LOPEZ AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet (1997) 349:1498–1504.
  • MURRAY CJ, LOPEZ AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet (1997) 349:1269–1276.
  • Morbidity and Mortality: 2002 Chartbook on Cardiovascular, Lung, and Blood Disease. NHLBI, NIH. May (2002).
  • MANNINO DM, HOMA DM, AKINBAMI LI, FORD ES, REDD SC: Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveil]. Summ. (2002) 51(6):1–16.
  • HANSEL TT, BARNES PJ: An Atlas of Chronic Obstructive Pulmonary Disease. The Parthenon Publishing Group, New York, USA (2004):1–115.
  • •This recently published book is a well written and illustrated review of both the basic mechanisms of COPD and its clinical management.
  • ANTHONISEN NR, CONNETT JE, KILEY JP et al.: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. I Am. Med Assoc. (1994) 272:1497–1505.
  • •A landmark study demonstrating the efficacy of smoking cessation in reducing the rate of decline of FEVI in COPD.
  • AMERICAN THORACIC SOCIETY: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am. I Respii: Crit. Care Med. (1995) 152:S77–S121.
  • CELLI BR, MACNEE W, and COMMITTEE MEMBERS: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. .1 (2004) 23:932–946.
  • BARNES PJ: Mechanisms in COPD: differences from asthma. Chest (2000) 117(2 Suppi.):10S–14S.
  • National Institutes of Health: National Heart, Lung, and Blood Institute: Global Initiative for Asthma. Global strategy for asthma management and prevention. National Institutes of Health: National Heart, Lung, and Blood Institute, Bethesda, USA (Report No. NIH-NHLBI 02–3659) (2002).
  • ••The most widely used recommendations for the management of asthma that emphasise the key role of inhaled corticosteroids.
  • BUHL R: Budesonide/formoterol for thetreatment for the treatment of asthma. Expert Opin. Pharmacother. (2003) 4:1393–1406.
  • OLIVIERI D, CHETTA A, DEL DONNO M et al: Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am. I Respir. Crit. Care Med. (1997) 155:1864–1871.
  • LLEWELLYN-JONES CG, HARRIS TA, STOCKLEY RA: Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am. J. Respir: Crit. Care Med. (1996) 153:616–621.
  • VERHOEVEN GT, HEGMANS JP, MULDER PG et al.: Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax (2002) 57:694–700.
  • CULPITT SV, MAZIAK W, LOUKIDIS S, NIGHTINGALE JA, MATTHEWS JL, BARNES PJ: Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am. I Respir: Crit. Care Med. (1999) 160:1635–1639.
  • O'BRIEN A, RUSSO-MAGNO P, KARKI A et al.: Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am. Respir: Crit. Care Med. (2001) 164:365–371.
  • CAL VERLEY P, BURGE PS, SPENCER S, ANDERSON JA, JONES PW: Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax (2003) 58:659–664.
  • ••Highlights the fact that contrary toconventional wisdom, most patients with COPD will respond to short-acting P-agonists if tested serially.
  • MOLLMAN H, WAGNER M, KRISHNASWAMI Set al.: Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbuhaler dry-powder inhalers to healthy subjects. Clin. Pharmacol (2001) 41:1329–1338.
  • THORSSON L, EDSBACKER S, KALLEN A, LOFDAHL CG: Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br. I Clin. Pharmacol (2001) 52:529–538.
  • CAZZOLA M, TESTI R, MATERA MG: Clinical pharmacokinetics of salmeterol. Chit. Pharmacokinet. (2002) 41:19–30.
  • BUCHWALD A, HOCHAUS G: Pharmacokinetic and pharmacodynamic aspects of salmeterol therapy. Int. J. Chit. Pharmacol Ther. (1998) 36:652–660.
  • CAZZOLA M, SANTANGELO G, PICCOLO A et al: Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol (1994) 7:103–107.
  • ABRAMSON MJ, WALTERS J, WALTERS EH: Adverse effects of beta-agonists: are they clinically relevant? Am. Respir. Med. (2003) 2:287–297.
  • HANANIA NA, SHARAFKHANEH A, BARBER R, DICKEY BF: Beta-agonist intrinsic efficacy. Measurement and clinical significance. Am. I Respir: Crit. Care Med. (2002) 165:1353–1358.
  • MAHLER DA, DONOHUE JF, BARBEE RA et al.: Efficacy of salmeterol xinafoate in the treatment of COPD. Chest (1999) 115:957–965.
  • RENNARD SI, ANDERSON W, ZUWALLACK R et al.: Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Arn. Respir: Crit. Care Med. (2001) 163:1087–1092.
  • KANTHAKUMAR K, CUNDELL DR, JOHNSON M et al.: Effect of salmeterol on human nasal epithelial cell ciliary beating: inhibition of the ciliotcodn, pyocyanin. Br..! Pharmacol (1994) 112:493–498.
  • CHAMBERS CB, CORRIGAN BW, NEWHOUSE MT: Salmeterol (5) speeds mucociliary transport (MCT) in healthy subjects. Am.J. Respir: Crit. Care Med. (1999) 159(3 Part 2):636.
  • BOLTON PB, LEFEVRE P, MCDONALD DM: Salmeterol reduces early- and late-phase plasma leakage and leukocyte adhesion in rat airways. Am. J. Respir. Crit. Care Med. (1997) 155:1428–1435.
  • PETERSON BT, GRIFFITH DE, CONNELLY JC, TATE RW: Differential effects of salmeterol on lung endothelial and epithelial leakage in sheep. I Appl. Physic] (1996) 80:1666–1673.
  • LEE E, LINDO T, JACKSON N et al.: Reversal of human neutrophil survival by leukotriene B4 receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors. Am. J. Respir: Crit. Care Med. (1999) 160:2079–2085.
  • DOWLING RB, RAYNER CFJ, RUTMAN A et al.: Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. Am. I Respir. Crit. Care Med. (1997) 155:327–336.
  • DOWLING RB, JOHNSON M, COLE PJ, WILSON R: Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur. Respir. (1998) 11:86–90.
  • HOCHHAUS G, MOLLMANN H, DERENDORF H, GONZALEZ-ROTHI RJ: Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. I. Chit. Pharmacol (1997) 37:881–892.
  • MACKIE AE, VENTRESCA GP, FULLER RW, BYE A: Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br. I Chit. Pharmacol (1996) 41:539–542.
  • THORSSON L, DAHLSTROM K, EDSBACKER S, KALLEN A, PAULSON J, WIREN J-E: Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br. I Chit. Pharmacol (1997) 43:155–161.
  • THORSSON L, EDSBACKER S, CONRADSON T-B: Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur: Respir. J. (1994) 7:1839–1844.
  • KIRBY S, FALCOZ C, DANIEL MJ et al:Salmeterol and fluticasone given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Eur.j Chit. Pharmacol (2001) 56:781–791.
  • CELIK G, KAYACAN 0, BEDER S, DURMAZ G: Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration (1999) 66:434–439.
  • BRUSASCO V, HODDER R, MIRAVITLLES M, KORDUCKI L, TOWSE L, KESTEN S: Health outcomes following treatment for six months with once daily tiotropium compared with twice 1824 daily salmeterol in patients with COPD. Thorax (2003) 58:399–404.
  • •This study reports data from two studies directly comparing tiotropium and salmeterol. Although only one [32] of the two studies reported better outcomes with tiotropium, those benefits persisted when the data was combined.
  • DONOHUE JF, VAN NOORD JA, BATEMAN ED et al.: A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest (2002) 122:47–55.
  • NIEWOEHNER DE, ERBLAND ML, DEUPREE RH et al., for the DEPARTMENT OF VETERANS AFFAIRS COOPERATIVE STUDY GROUP: The effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl. J. Med. (1999) 340:1941–1947.
  • •A key report demonstrating the efficacy of systemic corticosteroids in the management of acute exacerbations of COPD: 2 weeks of steroid therapy were as effective as 8 weeks.
  • AARON SD, VANDEMHEEN KL, HEBERT P et al.: Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl. J. Med. (2003) 348:2618–2625.
  • PAUWELS RA, LOFDAHL CG, LAMNEN LA et al.: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl. I Med. (1999) 340:1948–1953.
  • •A study of inhaled budesonide in patients with mild COPD that showed no effect on the rate of decline in FEVI although improvements in lung function were observed in those on steroids.
  • BURGE PS, CALVERLEY PM, JONES PW, SPENCER S, ANDERSON JA, MASLEN TK: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. 1 (2000) 320:1297-1303.
  • •A study of inhaled fluticasone in patients with severe COPD that documented improvements in lung function, Oa, and reduced the rate of acute exacerbations.
  • LUNG HEALTH STUDY RESEARCH GROUP: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl. I Med. (2000) 343:1902–1909.
  • PAGGIARO PL, DAHLE R, BAKRAN I, FRITH L, HOLLINGWORTH K, EFTHIMIOU J on behalf of the INTERNATIONAL COPD STUDY GROUP: Multicentre randomized placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet (1998) 351:773–780.
  • VAN DER VALK P, MONNINKHOF E, VAN DER PALEN J, ZIELHUIS G, VAN HER WAARDEN C: Effect of discontinuation of inhaled steroids in patients with chronic obstructive pulmonary disease: the COPE study. Am. J. Respir. Grit. Care Med. (2002) 166:1358–1363.
  • VESTBO J, SORENSEN T, LANGE P, BRIX A, TORRE P, VISKUM K: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (1999) 353:1819–1823.
  • •A study of mild COPD in which budesonide had no benefits on lung function, symptoms or exacerbations.
  • BOURBEAU J, ROULEAU MY, BOUCHER S: Randomized controlled trial of inhaled steroids in patients with chronic obstructive pulmonary disease. Thorax (1998) 53:477–482.
  • ALSAEEDI A, SIN DD, MCALISTER FA:The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am. J. Med. (2002) 113:59–65.
  • SINN DD, MCALISTER FA, PAUL MAN SF, ANTHONISEN NR: Contemporary management of chronic obstructive pulmonary disease. J. Am. Med. Assoc. (2003) 290:2301–2312.
  • SUTHERLAND ER, ALLMERS H, AYAS NT, VENN AJ, MARTIN RJ: Inhaled steroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax (2003) 58:937–941.
  • TAYLOR DR, HANCOX RJ: Interactionsbetween corticosteroids and beta-agonists. Thorax (2000) 55:595–602.
  • BARNES PJ: Scientific rationale for inhaledcombination therapy with long acting beta-2 agonists and corticosteroids. Ear: .1 (2002) 19:182-191.
  • •An excellent discussion of the potential molecular basis for the benefits of combined therapy - primarily in asthma.
  • GREENING AP, IND. PW, NORTHFIELD M, SHAW G: Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet (1994) 344:219–224.
  • DONOHUE JF, KALBERG C, EMMETT A, MERCHANT K, KNOBIL K: Fluticasone salmeterol combination (250/50) provides greater improvement in lung function and symptoms than the combination of ipratropium/albuterol in patients with COPD. Chest (2003) 124(4 Suppl.):128S.
  • CAZZOLA M, NOSCHESE P, CENTANNI S et al.: Salmeterol/fluticasone propionate in a single inhaler device versus theophylline+fluticasone propionate in patients with COPD. Palm. Pharmacol. Ther. (2004) 17:141–145.
  • CALVERLEY P, PAUWELS R, VESTBO J et al, for the TRISTAN Study Group: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet (2003) 361:449–456.
  • ••A pivotal study of fluticasone plussalmeterol in Europe.
  • HANANIA NA, DARKEN P, HORSTMAN D et al.: The efficacy and safety of fluticasone propionate (250mcg)/salmeterol (50mcg) combined in the Diskus inhaler for the treatment of COPD. Chest (2003) 124:834–843.
  • ••A pivotal study of fluticasone plussalmeterol submitted to the US FDA.
  • MAHLER DA, WIRE P, HORSTMAN D et al.: Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir Crit. Care Med. (2002) 166:1084–1091.
  • CAZZOLA M, DI LORENZO G, DI PERNA F, CALDERARO F, TESTI R, CENTANNI S: Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest (2000) 118:1576–1581.
  • CALVERLEY PM, BOONSAWAT W, CSEKE Z, ZHONG N, PETERSON S, OLSSON H: Maintenance therapy with budesonide and formoterol in chronic
  • •• obstructive pulmonary disease. Eur. Respir. J. (2003) 22:912–919.
  • SZAFRANSKI W, CUKIER A, RAMIREZ A et al.: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir (2003) 21:74–81.
  • SORIANO JB, VESTBO J, PRIDE NB, KIRI V, MADEN C, MATER WC: Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur. Respir. J. (2002) 20:819–825.
  • •An observational study of prescription practices in the UK that suggests there is a mortality advantage to the use of combined fluticasone plus salmeterol.
  • WISE R, CONNETT J, SCANLON P FOR THE LUNG HEALTH STUDY RESEARCH GROUP: Inhaled triamcinolone and chronic obstructive pulmonary disease (letter to the editor). N Engl. J. Med. (2001) 344:1554–1555.
  • JOHNELL 0, PAUWELS R, LOFDAHL CG et al.: Bone mineral density in chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur. Respir (2002) 19:1058–1063.
  • DAVIS KJ, CLARK D, KNOBIL K: Inhaled corticosteroid use and risk of non-vertebral fracture among adults with chronic obstructive pulmonary disease in UK general practice. Chest (2003) 124(4 Suppl.):166S.
  • JOHANNES CB, SCHNEIDER G, DUBE T, DAVIS KJ, WALKER AM: The risk of non-vertebral fracture related to inhaled corticosteroid exposure among adults with physician-diagnosed respiratory disease. Chart (2003) 124(4 Suppl.):170S.
  • LEE TA, BARTLE B, XU J, DAVIS KJ, WEISS KB: The association between inhaled corticosteroid use and fractures in veterans with chronic obstructive pulmonary disease. Chest (2003) 124(4 Suppl.) :166S.
  • SUISSA S, BALTZAN M, KREMER R, ERNST P: Inhaled and nasal corticosteroid use and the risk of fracture. Am. J. Respir. Grit. Care Med. (2004) 169:83–88.
  • LEE TA, WEISS KB: Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am. I Respir. Crit. Care Med. (2004) 169:855–859.
  • CUMMING RG, MITCHELL P, LEEDER SR: Use of inhaled corticosteroids and the risk of cataracts. N Engl. I Med. (1997) 337:8–14.
  • GARBE E, SUISSA S, LELORIER J: Association of inhaled corticosteroid use with cataract extraction in elderly patients. J. Am. Med. Assoc. (1998) 280:539–543.
  • SMEETH L, BOULIS M, HUBBARD R, FLETCHER AE: A population based case-control study of cataract and inhaled corticosteroids. Br. J. Opthalmol (2003) 87:1247–1251.
  • LI JTC, FORD LB, CHEVINSKY P et al:Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. j Allergy Clin. Immunol (1999) 103:1062–1068.
  • SALMETEROL MULTICENTRE ASTHMA RESEARCH TRIAL (SMART): interim analysis shows increased risk of asthma related deaths. Ceylon Med. j (2003) 48:99.
  • AU DH, CURTIS JR, EVERY NR, MCDONELL MB, FIHN SD: Association between inhaled P-agonists and the risk of unstable angina and myocardial infarction. Chest (2002) 121:846–851.
  • FERGUSON GT, FUNCK-BRETANO C, FISCHR T, DARKEN P, REISNER C: Cardiovascular safety of salmeterol in COPD. Chart (2003) 123:1817–1824.
  • ••A pooled analysis of seven clinical trials ofsalmeterol showing no increased risk of adverse cardiovascular events.

Websites

  • http://www.who.int/whr/ 192002/index.htm WORLD HEALTH ORGANIZATION: The World Health Report 2002. Reducing risks, promoting healthy life. Annex Table 2: Deaths by cause, sex and mortality stratum in WHO Regions, estimates for 2001.
  • http://www.goldcopd.com GOLD guidelines. Updated in 2003.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.